



Public Health
England

Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs

Surveillance Update: August 2019

Survey conducted by:

National Infections Service, Public Health England

Survey supported by:

Public Health Wales and Public Health Agency Northern Ireland

Further Information:

Information on the Unlinked Anonymous Monitoring Surveys can be found at:

<https://www.gov.uk/government/publications/people-who-inject-drugs-hiv-and-viral-hepatitis-monitoring>

About these data tables

These tables present data from the Unlinked Anonymous Monitoring (UAM) Survey of People Who Inject Drugs (PWID) in contact with specialist services. This annual cross-sectional survey is co-ordinated by Public Health England, with support from Public Health Wales and Public Health Agency Northern Ireland. It is completed by people who inject psychoactive drugs. These data tables are updated annually and made available on the Public Health England GOV.UK website. Data from the biennial survey of people who inject image and performance enhancing drugs can be found in a separate set of tables published on the same webpage. The data within these tables are discussed in an accompanying report which is also available on the Public Health England GOV.UK website.

Data are presented separately for the whole of England, Wales and Northern Ireland, and sub-divided by country and PHE region. In some of these areas regional breakdowns could not be provided due to small numbers. Regional level data should be interpreted cautiously as figures may be from a small number of sites or a single site. For clarity, percentages are given to two significant figures. Confidence intervals are not presented but are available for the main findings within the accompanying HPR.

This set of data tables presents data for the period 2008 to 2018. Data from the survey for earlier years (the survey has been running since 1990) can be found in past sets of data tables which are available via the Public Health England GOV.UK website.

Suggested citation

For citation purposes the following is suggested: Public Health England, National Infection Service. Unlinked Anonymous Monitoring Survey of People Who Inject Drugs: Data tables. August 2019. London, Public Health England.

Summary of survey methodology

This voluntary unlinked anonymous survey recruits people who inject drugs through specialist agencies within England, Wales and Northern Ireland. These agencies provide a range of services to those who inject drugs, from medical treatment to needle and syringe programmes and outreach work. People using these services that are either currently injecting drugs or who have done so previously are asked to take part in the survey by service staff. Those who agree to take part provide a biological specimen that is tested anonymously for HIV, hepatitis C and hepatitis B. Behavioural and limited demographic information is collected through a brief anonymous subject-completed questionnaire linked to the specimen but unlinked from any client identifying information. This includes questions on the uptake of diagnostic (voluntary confidential) testing for HIV and hepatitis C, hepatitis B vaccination and the sharing of injecting equipment; participants may opt out of answering any questions. The questions asked have varied over time.

The biological sample collected in the survey was changed from an oral fluid sample to a dried blood spot (DBS) sample during 2009 and 2010. From 2011 onwards, only DBS samples have been collected. The sensitivities of the tests on a DBS sample for antibodies to HIV, hepatitis C and hepatitis B core antigen, and that on an oral fluid sample for antibodies to HIV, are all close to 100%. However, the sensitivity of the oral fluid sample test for antibodies to hepatitis C is about 92% and that for antibodies to the hepatitis B core antigen is about 75%. Figures in these tables have been adjusted to account for this difference.

The prevalence of HCV RNA, an indicator of chronic HCV infection, has been measured in the 2017 and 2018 surveys and has been retrospectively measured for the survey years 2011 and 2014-2016 (data from 2012 and 2013 are awaited). Retrospective analysis of HCV RNA (2011-2016) was performed as part of the EPIToPE study, funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme (Grant Reference Number RP-PG-0616-20008). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Number of sites¹ recruiting participants each year: 2008-2018

Area	Survey Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
London	12	13	10	9	16	13	12	11	8	8	10
Elsewhere in England	42	40	46	46	47	51	51	45	47	52	51
Wales	4	5	5	5	6	5	5	4	5	5	5
Northern Ireland	3	2	4	4	4	4	4	4	4	3	3
Total	61	60	65	64	73	73	72	64	64	68	69

¹ Sites are defined as geographical centres which have collected ten or more samples in the reporting year.

Contents

Table 1: Characteristics of the people who inject drugs recruited across England, Wales and Northern Ireland: 2008-2018

Table 2: HIV prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 3: Hepatitis B prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 4: Hepatitis C prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 5: Level of direct sharing among current injectors by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 6: Level of direct & indirect sharing among current injectors by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 7: Self-reported hepatitis B vaccine uptake among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 8: Uptake of voluntary confidential testing (VCT) for HIV among people who inject drugs by age and HIV status; England, Wales and Northern Ireland: 2008-2018

Table 9: Uptake of voluntary confidential testing (VCT) for hepatitis C virus (HCV) among people who inject drugs by age and HCV status; England, Wales and Northern Ireland: 2008-2018

Table 10: Symptoms of an injection site infection among those who injected during the preceding year by gender and age; England, Wales and Northern Ireland: 2008-2018

Table 11: Sexual intercourse (anal or vaginal), number of sexual partners and condom use during the preceding year; England, Wales and Northern Ireland: 2008-2018

Regional Tables: *HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use : 2008-2018*

Table 12: England

Table 13: London

Table 14: East of England

Table 15: South East

Table 16: South West

Table 17: West Midlands

Table 18: North West

Table 19: Yorkshire & Humber

Table 20: East Midlands

Table 21: North East

Table 22: Wales

Table 23: Northern Ireland

Table 24: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks and condom use in those who began injecting in the last three years (recent initiates): 2008-2018

Abbreviations and footnotes used in this set of data tables

List of abbreviations used in this data set:

Anti-HIV	=	antibodies to HIV
Anti-HBc	=	antibodies to hepatitis B core antigen, a marker of current or past hepatitis B infection
HBsAg	=	hepatitis B surface antigen, a marker of current hepatitis B infection
Anti-HCV	=	antibodies to hepatitis C virus
HCV RNA	=	hepatitis C RNA, a marker of current hepatitis C infection
HBV	=	hepatitis B virus
HCV	=	hepatitis C virus
VCT	=	voluntary confidential testing
DBS	=	dried blood spot

List of footnotes used in this data set:

- ℞ Sites are defined as geographical centres who have collected ten or more samples in the reporting year.
- ~ Age and gender not provided by all participants.
- Currently prescribed a detox or maintenance drug medicine.
- Self-reports of ever receiving money, goods or drugs in exchange for sex.
- † Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.
- § The sensitivity of the oral fluid test for anti-HBc is approximately 75%.
Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100. In 2018, HBV prevalence data for all years were updated to reflect changes to the laboratory cut off value to indicate anti-HBc positivity.
- †† HBsAg Prevalence = (number of samples tested HBsAg positive / number of samples tested anti-HBc positive)x100. Samples provided may be insufficient for additional (HBsAg) testing.
- ††† The sensitivity of the oral fluid test for antibodies to hepatitis C (anti-HCV) is approximately 92%.
- †††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.
« HCV RNA Prevalence = (number of samples tested HCV RNA positive / number of samples tested anti-HCV positive)x100. Samples provided may be insufficient for additional (RNA) testing.
- ‡ Sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.
- ‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.
- * Self-reported uptake of a least 1 dose of the HBV vaccine
- ^ Recent VCT refers to testing within the current or previous survey year.
- ¥ Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.
- ** Reported no treatment or self-treatment of a swelling containing pus (abscess), sore or open wound at an injection site in preceding year.
- a PWID reporting injecting in the last 12 months

Table 1: Characteristics of people who inject drugs recruited across England, Wales and Northern Ireland: 2008-2018

	Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Injected drugs in the last year	77%	75%	71%	69%	71%	72%	70%	73%	72%	71%	70%
Number injected drugs in the last year	2,368	2,305	2,162	1,793	2,215	2,194	2,088	1,896	1,940	1,784	1,873
Total number answering question	3,066	3,074	3,034	2,603	3,110	3,032	2,969	2,606	2,708	2,509	2,690
Under 25 years old ~	13%	13%	11%	8.8%	8.8%	6.0%	5.8%	4.3%	2.6%	2.8%	2.4%
Number aged <25 years	409	400	341	239	287	185	175	116	71	71	68
Total number answering question	3,066	3,120	3,153	2,731	3,254	3,093	3,037	2,678	2,758	2,573	2,781
Female gender ~	26%	26%	25%	25%	26%	26%	27%	27%	28%	29%	28%
Number female	826	851	790	683	851	817	826	718	793	766	791
Total number answering question	3,170	3,229	3,223	2,785	3,336	3,108	3,067	2,696	2,784	2,610	2,810
Current treatment for drug use *	70%	73%	73%	74%	67%	69%	69%	70%	70%	78%	77%
Number reporting current treatment	2,226	2,352	2,360	2,060	2,231	2,137	2,120	1,881	1,940	2,040	2,122
Total number answering question	3,178	3,238	3,230	2,791	3,337	3,119	3,061	2,690	2,775	2,601	2,767
Ever used a needle exchange	93%	93%	92%	93%	92%	92%	90%	91%	92%	92%	91%
Number reporting use of needle exchange	2,960	3,003	2,988	2,586	3,072	2,866	2,760	2,439	2,544	2,363	2,507
Total number answering question	3,181	3,244	3,241	2,786	3,333	3,120	3,065	2,691	2,774	2,577	2,744
Ever been in prison	68%	72%	70%	71%	72%	71%	69%	67%	68%	67%	67%
Number reporting ever being imprisoned	2,106	2,266	2,186	1,922	2,319	2,194	2,084	1,793	1,872	1,683	1,807
Total number answering question	3,089	3,144	3,132	2,704	3,241	3,072	3,022	2,659	2,763	2,497	2,684
Homeless in the last year	34%	35%	28%	28%	32%	35%	34%	37%	36%	39%	47%
Number reporting being homeless in the last year	1,041	1,084	875	752	1,045	1,075	1,025	983	1,007	990	1,270
Total number answering question	3,067	3,140	3,136	2,712	3,260	3,078	3,023	2,659	2,762	2,514	2,702
Ever traded sex for money, goods or drugs **				14%	13%	12%	12%	13%	13%	13%	13%
Number reporting ever trading sex				334	384	345	358	335	361	322	345
Total number answering question				2,412	2,997	3,000	2,924	2,586	2,694	2,451	2,615
Among those who had injected in preceding four weeks											
Stimulant drugs											
Proportion injecting crack	35%	29%	29%	32%	36%	37%	40%	46%	53%	51%	60%
Number reporting crack injection	640	526	499	421	596	615	627	659	766	668	863
Total number answering question	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458	1,308	1,439
Proportion injecting cocaine	11%	7.7%	6.6%	8.5%	8.7%	6.9%	7.6%	9.7%	10%	14%	13%
Number reporting cocaine injection	199	140	112	110	145	115	119	139	150	181	184
Total number answering question	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458	1,308	1,439
Proportion injecting amphetamine	18%	17%	18%	23%	22%	23%	24%	17%	17%	16%	13%
Number reporting amphetamine injection	330	314	308	302	364	382	375	247	244	205	184
Total number answering question	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458	1,308	1,439
Higher risk injection sites											
Proportion injecting into their groin	32%	35%	34%	35%	35%	38%	38%	38%	40%	39%	37%
Number reporting groin injection	579	618	567	459	584	634	598	548	598	514	544
Total number answering question	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478	1,330	1,459
Proportion injecting into their hands	25%	28%	27%	27%	25%	26%	30%	29%	27%	25%	28%
Number reporting injecting into their hands	453	491	453	361	430	435	475	418	398	337	412
Total number answering question	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478	1,330	1,459
Proportion injecting into their legs	18%	19%	18%	21%	20%	21%	23%	26%	26%	25%	26%
Number reporting injecting into their legs	321	331	311	279	342	356	371	375	386	333	378
Total number answering question	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478	1,330	1,459
Proportion injecting into their feet	10%	12%	11%	11%	11%	11%	11%	13%	12%	12%	12%
Number reporting injecting into their feet	189	211	190	149	190	178	181	191	173	164	168
Total number answering question	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478	1,330	1,459

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 2: HIV prevalence[†] in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All		Anti-HIV Prevalence [†]	1.6%	1.5%	1.1%	1.2%	1.3%	1.1%	1.0%	0.96%	0.85%	0.87%	1.2%
		Number of samples anti-HIV positive	51	49	35	35	43	34	31	26	24	23	34
		Total number of samples collected	3,209	3,289	3,288	2,838	3,389	3,144	3,091	2,721	2,812	2,656	2,826
Gender ~	Male	Anti-HIV Prevalence [†]	1.7%	1.5%	1.1%	1.4%	1.3%	1.2%	1.3%	1.0%	0.85%	0.92%	1.3%
		Number of samples anti-HIV positive	40	35	27	29	32	28	28	20	17	17	27
		Total number of samples collected	2,344	2,378	2,433	2,102	2,485	2,291	2,241	1,978	1,991	1,844	2,018
	Female	Anti-HIV Prevalence [†]	1.3%	1.4%	0.76%	0.88%	1.2%	0.73%	0.36%	0.84%	0.88%	0.78%	0.88%
		Number of samples anti-HIV positive	11	12	6	6	10	6	3	6	7	6	7
		Total number of samples collected	826	851	790	683	851	817	826	718	793	766	791
Age ~	Under 25	Anti-HIV Prevalence [†]	1.0%	0.25%	0.59%	0.84%	0.70%	0.54%	0.57%	1.7%	0%	0%	0%
		Number of samples anti-HIV positive	4	1	2	2	2	1	1	2	0	0	0
		Total number of samples collected	409	400	341	239	287	185	175	116	71	71	68
	25 to 34	Anti-HIV Prevalence [†]	1.5%	1.1%	0.58%	1.1%	0.84%	0.72%	0.41%	0.90%	0.92%	0.61%	0.77%
		Number of samples anti-HIV positive	19	14	7	11	10	8	4	7	7	4	5
		Total number of samples collected	1,296	1,246	1,214	1,027	1,186	1,107	964	782	765	652	646
	35 and over	Anti-HIV Prevalence [†]	2.0%	2.1%	1.5%	1.4%	1.6%	1.3%	1.3%	0.96%	0.83%	0.97%	1.4%
		Number of samples anti-HIV positive	27	31	24	20	29	23	24	17	16	18	28
		Total number of samples collected	1,361	1,474	1,598	1,465	1,781	1,801	1,898	1,780	1,922	1,850	2,066

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 3: Hepatitis B prevalence^{††} in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018**Note:** Anti-HBc is a marker for current or past hepatitis B infection, HBsAg is a marker for current infection.

			Year												
			2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type			Oral fluid [§]	Oral fluid [§]	DBS	Oral fluid [§]	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	
All	Anti-HBc Prevalence ^{††}		18%	17%		16%		15%	16%	16%	14%	14%	12%	11%	9.1%
	Proportion anti-HBc positive		13%	13%	11%	14%	15%	15%	16%	16%	14%	14%	12%	11%	9.1%
	Number of samples anti-HBc positive		425	371	59	150	329	438	536	497	442	376	349	301	258
	Total number of samples collected		3,207	2,753	536	1,077	2,211	2,838	3,388	3,121	3,091	2,718	2,795	2,655	2,825
Gender ~	Male	Anti-HBc Prevalence ^{††}	18%	17%		17%		16%	17%	16%	15%	14%	13%	12%	9.3%
		Proportion anti-HBc positive	14%	14%	10%	13%	16%	16%	17%	16%	15%	14%	13%	12%	9.3%
		Number of samples anti-HBc positive	322	280	40	110	259	343	419	369	346	286	263	227	187
		Total number of samples collected	2,342	1,982	396	817	1,616	2,102	2,484	2,273	2,241	1,975	1,981	1,843	2,017
	Female	Anti-HBc Prevalence ^{††}	16%	15%		14%		13%	12%	15%	12%	12%	11%	9.3%	9.0%
		Proportion anti-HBc positive	12%	12%	14%	16%	11%	13%	12%	15%	12%	12%	11%	9.3%	9.0%
		Number of samples anti-HBc positive	99	84	19	38	62	90	105	123	95	87	85	71	71
		Total number of samples collected	826	714	137	233	557	683	851	812	826	718	786	766	791
Age ~	Under 25	Anti-HBc Prevalence ^{††}	4.2%	4.3%		8.0%		5.4%	4.9%	3.2%	2.3%	2.6%	2.8%	1.4%	2.9%
		Proportion anti-HBc positive	3.2%	4.0%	1.0%	7.5%	6.8%	5.4%	4.9%	3.2%	2.3%	2.6%	2.8%	1.4%	2.9%
		Number of samples anti-HBc positive	13	12	1	10	14	13	14	6	4	3	2	1	2
		Total number of samples collected	409	299	101	134	207	239	287	185	175	115	71	71	68
	25 to 34	Anti-HBc Prevalence ^{††}	11%	10%		8.4%		9.3%	8.7%	9.1%	5.8%	5.3%	4.6%	4.3%	3.1%
		Proportion anti-HBc positive	7.9%	8.0%	7.1%	5.9%	8.6%	9.3%	8.7%	9.1%	5.8%	5.3%	4.6%	4.3%	3.1%
		Number of samples anti-HBc positive	103	82	16	23	71	95	103	100	56	41	35	28	20
		Total number of samples collected	1,296	1,020	226	387	827	1,027	1,186	1,101	964	781	762	652	646
	35 and over	Anti-HBc Prevalence ^{††}	28%	26%		24%		22%	22%	22%	20%	18%	16%	14%	11%
		Proportion anti-HBc positive	21%	20%	20%	22%	21%	22%	22%	22%	20%	18%	16%	14%	11%
		Number of samples anti-HBc positive	282	253	39	111	235	320	393	385	372	322	305	264	232
		Total number of samples collected	1,359	1,282	192	495	1,103	1,465	1,780	1,784	1,898	1,779	1,909	1,849	2,065
Among those anti-HBc positive		HBsAg Prevalence ^{†††}					5.3%	6.2%	3.8%	4.2%	3.2%	3.5%	1.7%	4.7%	
		Number of samples HBsAg positive						21	32	18	18	11	12	5	12
		Total number of samples collected						400	519	470	431	343	344	295	258

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 4: Hepatitis C prevalence^{††††} in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018**Note:** Anti-HCV positivity indicates a current or past infection. HCV RNA positivity indicates a current infection.

			Year												
			2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type			Oral fluid ^{††}	Oral fluid ^{††}	DBS	Oral fluid ^{††}	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
All	Anti-HCV Prevalence ^{†††}		43%	47%		47%		43%	47%	49%	49%	50%	53%	51%	54%
	Proportion anti-HCV positive		40%	43%	47%	41%	48%	43%	47%	49%	49%	50%	53%	51%	54%
	Number of samples anti-HCV positive		1,274	1,183	252	442	1,051	1,234	1,601	1,543	1,517	1,371	1,462	1,366	1,523
	Total number of samples collected		3,209	2,753	536	1,077	2,211	2,838	3,389	3,144	3,091	2,721	2,774	2,655	2,826
Gender ~	Male	Anti-HCV Prevalence ^{†††}	43%	47%		48%		45%	48%	48%	50%	50%	53%	52%	55%
		Proportion of samples anti-HCV positive	40%	43%	45%	41%	49%	45%	48%	48%	50%	50%	53%	52%	55%
		Number of samples anti-HCV positive	938	859	180	337	797	941	1,199	1,109	1,115	996	1,038	967	1,111
		Total number of samples collected	2,344	1,982	396	817	1,616	2,102	2,485	2,291	2,241	1,978	1,968	1,843	2,018
	Female	Anti-HCV Prevalence ^{†††}	41%	47%		42%		40%	45%	51%	47%	51%	52%	49%	51%
		Proportion of samples anti-HCV positive	38%	42%	52%	40%	41%	40%	45%	51%	47%	51%	52%	49%	51%
		Number of samples anti-HCV positive	313	301	71	93	231	275	383	415	388	364	407	376	402
		Total number of samples collected	826	714	137	233	557	683	851	817	826	718	778	766	791
Age ~	Under 25	Anti-HCV Prevalence ^{†††}	22%	26%		27%		22%	24%	28%	25%	28%	25%	25%	34%
		Proportion of samples anti-HCV positive	20%	21%	37%	25%	26%	22%	24%	28%	25%	28%	25%	25%	34%
		Number of samples anti-HCV positive	83	62	37	34	54	52	68	52	43	32	18	18	23
		Total number of samples collected	409	299	101	134	207	239	287	185	175	116	71	71	68
	25 to 34	Anti-HCV Prevalence ^{†††}	36%	38%		36%		36%	38%	42%	40%	40%	44%	40%	45%
		Proportion of samples anti-HCV positive	33%	35%	41%	31%	37%	36%	38%	42%	40%	40%	44%	40%	45%
		Number of samples anti-HCV positive	426	355	92	119	309	366	446	467	385	316	332	258	291
		Total number of samples collected	1,296	1,020	226	387	827	1,027	1,186	1,107	964	782	755	652	646
	35 and over	Anti-HCV Prevalence ^{†††}	56%	59%		58%		53%	57%	55%	56%	56%	57%	56%	57%
		Proportion anti-HCV positive	51%	54%	59%	54%	58%	53%	57%	55%	56%	56%	57%	56%	57%
		Number of samples anti-HCV positive	699	691	113	265	642	773	1,015	998	1,060	1,001	1,077	1,044	1,186
		Total number of samples collected	1,361	1,282	192	495	1,103	1,465	1,781	1,801	1,898	1,780	1,895	1,849	2,066
Among those anti-HCV positive		HCV RNA Prevalence ^{††}						58%			57%	56%	56%	49%	49%
		Number of samples HCV RNA positive						612			778	672	704	664	718
		Number of samples anti-HCV positive						1,054			1,362	1,205	1,260	1,352	1,453

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 5: Level of direct sharing among current injectors[‡] by gender and age; England, Wales and Northern Ireland: 2008-2018

Note: Direct sharing is defined as sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All		Level of direct sharing ‡	19%	19%	21%	17%	14%	16%	17%	16%	17%	18%	18%
		Number reporting direct sharing	343	339	363	224	236	265	259	227	241	231	261
		Total number answering question	1,798	1,814	1,701	1,305	1,660	1,622	1,540	1,406	1,430	1,281	1,419
Gender ~	Male	Level of direct sharing ‡	18%	17%	20%	16%	13%	15%	15%	14%	15%	17%	16%
		Number reporting direct sharing	235	234	254	160	167	188	181	146	157	159	163
		Total number answering question	1,328	1,382	1,299	1,020	1,261	1,219	1,169	1,056	1,063	946	1,026
	Female	Level of direct sharing ‡	23%	24%	27%	22%	17%	19%	21%	23%	23%	22%	25%
		Number reporting direct sharing	105	102	101	62	67	75	78	79	83	71	97
		Total number answering question	452	418	380	280	393	397	370	346	365	329	388
Age ~	Under 25	Level of direct sharing ‡	22%	27%	30%	24%	23%	31%	20%	25%	20%	23%	17%
		Number reporting direct sharing	60	71	64	33	41	38	24	16	10	10	8
		Total number answering question	272	264	215	137	181	121	118	65	49	43	46
	25 to 34	Level of direct sharing ‡	20%	20%	22%	17%	14%	17%	18%	21%	22%	23%	23%
		Number reporting direct sharing	159	147	150	89	93	111	100	99	95	87	88
		Total number answering question	802	751	691	523	643	646	557	466	440	382	383
	35 and over	Level of direct sharing ‡	17%	14%	18%	16%	12%	13%	15%	13%	14%	16%	16%
		Number reporting direct sharing	110	105	136	96	92	111	130	111	131	131	156
		Total number answering question	662	731	742	613	795	841	849	867	929	839	976

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 6: Level of direct & indirect sharing among current injectors^{##} by gender and age; England, Wales and Northern Ireland: 2008-2018

Note: Direct and Indirect sharing is defined as the sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All		Level of sharing (direct & indirect) ^{##}	40%	36%	39%	35%	34%	39%	38%	38%	39%	36%	39%
		Number reporting sharing	700	656	663	460	566	641	597	542	571	461	551
		Total number answering question	1,765	1,815	1,705	1,300	1,657	1,636	1,558	1,414	1,447	1,293	1,426
Gender ~	Male	Level of sharing (direct & indirect) ^{##}	38%	34%	37%	34%	32%	38%	36%	36%	37%	36%	36%
		Number reporting sharing	495	466	477	347	402	472	425	386	398	341	376
		Total number answering question	1,302	1,384	1,300	1,015	1,256	1,230	1,183	1,063	1,075	955	1,032
	Female	Level of sharing (direct & indirect) ^{##}	44%	44%	45%	40%	41%	42%	46%	44%	46%	36%	44%
		Number reporting sharing	198	185	174	111	160	166	171	154	172	118	171
		Total number answering question	445	417	383	281	395	399	373	347	370	332	389
Age ~	Under 25	Level of sharing (direct & indirect) ^{##}	40%	45%	49%	46%	45%	54%	51%	43%	43%	39%	28%
		Number reporting sharing	106	120	106	63	81	65	60	28	21	17	13
		Total number answering question	267	264	215	137	181	121	118	65	49	44	46
	25 to 34	Level of sharing (direct & indirect) ^{##}	41%	37%	38%	35%	34%	39%	38%	41%	44%	42%	41%
		Number reporting sharing	317	283	266	182	217	255	215	194	197	161	158
		Total number answering question	780	755	694	522	641	652	561	469	443	382	383
	35 and over	Level of sharing (direct & indirect) ^{##}	39%	31%	37%	34%	32%	37%	37%	37%	37%	32%	38%
		Number reporting sharing	255	226	271	205	250	313	315	319	346	273	370
		Total number answering question	653	730	742	610	793	848	862	872	943	847	983

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 7: Self-reported hepatitis B vaccine uptake* among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2008-2018

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All		Hepatitis B vaccine uptake *	72%	73%	74%	76%	75%	72%	72%	75%	72%	74%	72%
		Number reporting hepatitis B vaccine uptake	2,259	2,352	2,383	2,094	2,463	2,163	2,126	1,952	1,921	1,897	1,980
		Total number answering question	3,140	3,204	3,199	2,748	3,287	3,011	2,936	2,595	2,682	2,572	2,744
Gender ~	Male	Hepatitis B vaccine uptake *	72%	73%	75%	76%	75%	72%	72%	75%	72%	74%	73%
		Number reporting hepatitis B vaccine uptake	1,650	1,715	1,783	1,574	1,836	1,588	1,542	1,419	1,373	1,327	1,432
		Total number answering question	2,298	2,344	2,381	2,061	2,440	2,207	2,136	1,895	1,910	1,802	1,959
	Female	Hepatitis B vaccine uptake *	72%	74%	74%	76%	74%	72%	73%	76%	71%	74%	70%
		Number reporting hepatitis B vaccine uptake	587	611	577	513	619	566	577	529	545	562	542
		Total number answering question	814	831	782	675	834	784	792	694	765	757	778
Age ~	Under 25	Hepatitis B vaccine uptake *	69%	73%	66%	76%	70%	66%	67%	68%	54%	64%	48%
		Number reporting hepatitis B vaccine uptake	272	292	223	179	196	117	112	75	36	44	31
		Total number answering question	396	399	338	235	282	178	168	111	67	69	65
	25 to 34	Hepatitis B vaccine uptake *	77%	77%	79%	79%	78%	75%	75%	76%	70%	72%	68%
		Number reporting hepatitis B vaccine uptake	975	939	946	802	916	799	690	577	519	467	431
		Total number answering question	1,270	1,226	1,191	1,011	1,174	1,067	922	762	743	645	630
	35 and over	Hepatitis B vaccine uptake *	69%	71%	73%	74%	74%	71%	72%	76%	73%	75%	74%
		Number reporting hepatitis B vaccine uptake	925	1,025	1,140	1,070	1,288	1,228	1,305	1,286	1,351	1,351	1,496
		Total number answering question	1,345	1,447	1,568	1,438	1,740	1,733	1,813	1,702	1,842	1,809	2,014

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 8: Uptake of voluntary confidential testing (VCT) for HIV among people who inject drugs by age; England, Wales and Northern Ireland: 2008-2018

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All	Ever HIV VCT uptake		73%	76%	76%	78%	79%	76%	77%	79%	78%	78%	80%
	Number reporting ever uptake of a HIV VCT		2,261	2,376	2,368	2,105	2,541	2,306	2,285	2,081	2,116	1,908	2,088
	Recent^ HIV VCT for HIV		31%	34%	33%	35%	35%	31%	32%	35%	31%	31%	38%
	Number reporting recent uptake of a HIV VCT		957	1,078	1,023	950	1,129	932	938	918	844	768	991
Total number answering question			3,111	3,143	3,134	2,687	3,199	3,018	2,958	2,620	2,718	2,444	2,616
Age ~	Under 25	Ever HIV VCT uptake	64%	72%	65%	67%	68%	65%	64%	65%	74%	74%	54%
		Number reporting a VCT for HIV	250	276	210	152	185	114	105	74	50	49	33
		Total number answering question	389	381	324	228	274	176	165	114	68	66	61
	25 to 34	Ever HIV VCT uptake	71%	74%	73%	76%	80%	76%	75%	78%	73%	77%	77%
		Number reporting a VCT for HIV	907	892	864	750	902	814	697	594	544	463	464
		Total number answering question	1,271	1,212	1,177	987	1,133	1,073	930	760	742	604	599
	35 and over	Ever HIV VCT uptake	76%	78%	80%	82%	81%	78%	80%	81%	80%	79%	81%
		Number reporting a VCT for HIV	1,005	1,109	1,226	1,151	1,378	1,356	1,458	1,397	1,502	1,365	1,568
		Total number answering question	1,328	1,420	1,533	1,410	1,702	1,739	1,827	1,725	1,879	1,735	1,924
Among those anti-HIV positive		Proportion aware of HIV infection	64%	63%	89%	88%	95%	96%	85%	84%	95%	90%	97%
		Number aware of their HIV infection	28	27	25	28	37	27	22	21	21	18	28
		Total number answering question	44	43	28	32	39	28	26	25	22	20	29

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 9: Uptake of voluntary confidential testing (VCT) for hepatitis C virus (HCV) among people who inject drugs by age; England, Wales and Northern Ireland: 2008-2018

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All	Ever HCV VCT Uptake		78%	82%	82%	84%	85%	83%	84%	86%	85%	84%	85%
	Number reporting ever HCV VCT uptake		2,400	2,560	2,550	2,229	2,684	2,524	2,515	2,273	2,307	2,091	2,285
	Recent ^ HCV VCT Uptake		37%	41%	39%	41%	40%	35%	36%	38%	34%	36%	47%
	Number reporting recent HCV VCT uptake		1,132	1,275	1,199	1,091	1,272	1,054	1,078	1,014	925	887	1,253
Total number answering question			3,080	3,112	3,101	2,641	3,169	3,039	2,997	2,638	2,730	2,495	2,686
Age ~	Under 25	HCV VCT Uptake	68%	76%	71%	76%	72%	71%	69%	73%	76%	72%	60%
		Number reporting a VCT for HCV	262	287	226	170	197	127	118	83	52	48	38
		Total number answering question	383	378	318	224	272	178	171	114	68	67	63
	25 to 34	HCV VCT Uptake	77%	81%	81%	83%	85%	82%	82%	83%	80%	83%	82%
		Number reporting a VCT for HCV	970	969	938	805	957	884	772	634	592	511	503
		Total number answering question	1,257	1,197	1,163	971	1,129	1,077	942	764	742	619	616
	35 and over	HCV VCT Uptake	81%	85%	86%	87%	86%	85%	87%	88%	87%	85%	87%
		Number reporting a VCT for HCV	1,062	1,199	1,312	1,201	1,456	1,486	1,599	1,537	1,638	1,496	1,718
		Total number answering question	1,317	1,407	1,528	1,386	1,687	1,751	1,846	1,737	1,888	1,766	1,974
Among those anti-HCV positive *		Proportion aware of ever HCV infection	50%	51%	55%	51%	54%	47%	52%	52%	52%	66%	65%
		Number aware of their HCV infection	555	631	711	530	703	629	678	619	663	661	727
		Total number answering question	1,112	1,242	1,303	1,035	1,308	1,344	1,297	1,184	1,271	1,008	1,126
Among those anti-HCV positive & HCV RNA positive		Proportion aware of current HCV infection										55%	50%
		Number aware of their HCV infection										268	268
		Total number answering question										484	538

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 10: Symptoms of an injection site infection among those who injected during the preceding year by gender and age; England, Wales and Northern Ireland: 2017-2018

Note: Symptoms of an injection site infection include reporting a swelling containing pus (abscess), sore or open wound at an injection site in the preceding year.

			Year						
			2013	2014	2015	2016	2017	2018	
All		Symptom of injection site infection Number reporting symptom Total number answering question	Questions regarding symptoms of injection site infections have been updated. As such, data collected in 2017 & 2018 is not comparable to previously collected data. Data from previous years can be found online: https://www.gov.uk/government/statistics/people-who-inject-drugs-hiv-and-viral-hepatitis-monitoring				50%	54%	
Gender ~	Male	Symptom of injection site infection §§ Number reporting symptom Total number answering question					48%	52%	
		Female					Symptom of injection site infection §§ Number reporting symptom Total number answering question	53%	59%
	Age ~						Under 25	Symptom of injection site infection §§ Number reporting symptom Total number answering question	33%
		25 to 34						Symptom of injection site infection §§ Number reporting symptom Total number answering question	49%
35 and over							Symptom of injection site infection §§ Number reporting symptom Total number answering question	50%	54%
		All					Did not seek health care treatment ** Number not seeking care Total reporting injection site infection	56%	58%

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 11: Sexual intercourse (anal or vaginal), number of sexual partners and condom use during the preceding year; England, Wales and Northern Ireland: 2008-2018

			Year										
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
All	Proportion having sex (anal or vaginal) in preceding year		75%	74%	75%	73%	73%	70%	68%	66%	64%	65%	60%
	Number having sex in preceding year		2,326	2,318	2,323	1,997	2,377	2,120	2,001	1,731	1,716	1,583	1,592
	Total number answering question		3,107	3,145	3,116	2,738	3,254	3,034	2,945	2,604	2,693	2,432	2,636
Among those who had (anal or vaginal) sex in the preceding year													
All	Proportion with two or more partners		42%	41%	44%	46%	44%	41%	40%	40%	37%	40%	40%
	Number with two or more partners		944	897	961	875	1,012	838	768	676	607	596	613
	Total number answering question		2,250	2,205	2,209	1,921	2,312	2,026	1,917	1,677	1,634	1,491	1,530
Among those with two or more (anal or vaginal) sexual partners in preceding year													
All	Proportion always using a condom		22%	20%	22%	19%	17%	18%	22%	22%	22%	19%	19%
	Number always using a condom		194	168	196	150	153	128	143	124	114	93	92
	Total number answering question		889	844	878	777	924	705	657	576	508	484	478
Gender ~	Male	Proportion always using a condom	21%	17%	22%	19%	15%	18%	22%	20%	23%	17%	18%
		Number always using a condom	145	108	157	118	111	101	117	87	89	63	65
		Total number answering question	688	648	698	632	723	563	529	438	391	361	354
	Female	Proportion always using a condom	25%	31%	21%	22%	21%	19%	21%	27%	21%	25%	21%
		Number always using a condom	48	59	36	32	42	26	26	37	25	30	26
		Total number answering question	189	191	169	143	196	138	126	137	117	122	122
Age ~	Under 25	Proportion always using a condom	19%	17%	18%	14%	13%	7.4%	12%	17%	17%	20%	19%
		Number always using a condom	28	28	26	14	16	6	7	7	5	6	3
		Total number answering question	144	167	147	102	122	81	60	42	29	30	16
	25 to 34	Proportion always using a condom	17%	18%	22%	17%	14%	16%	17%	19%	19%	22%	19%
		Number always using a condom	76	66	84	58	57	49	46	40	36	36	32
		Total number answering question	436	368	381	340	413	304	264	214	194	164	171
	35 and over	Proportion always using a condom	28%	23%	26%	23%	21%	23%	27%	24%	26%	18%	20%
		Number always using a condom	78	68	84	72	77	72	89	77	72	51	56
		Total number answering question	275	290	327	319	368	315	326	316	281	285	285

Please refer to page 4 for abbreviations and footnotes to assist in interpreting this data

Table 12: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; England: 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	1.5%	1.6%		1.2%		1.3%	1.4%	1.2%	1.0%	1.0%	0.85%	0.88%	1.2%
Number of samples anti-HIV positive	44	46		35		32	43	32	27	23	21	21	30
Total number of samples collected	2,893	2,962		2,899		2,485	2,982	2,782	2,667	2,307	2,469	2,373	2,571
Anti-HBc Prevalence ^{††}	19%	18%		17%		16%	17%	17%	15%	15%	13%	12%	9.3%
Proportion of samples anti-HBc positive	14%	15%	11%	16%	16%	16%	17%	17%	15%	15%	13%	12%	9%
Number of samples anti-HBc positive	402	355	59	142	317	396	502	462	403	336	320	283	240
Total number of samples collected	2,892	2,426	536	881	2,018	2,485	2,982	2,759	2,667	2,305	2,453	2,372	2,570
Anti-HCV Prevalence ^{†††}	44%	49%		49%		45%	49%	50%	50%	52%	54%	52%	55%
Proportion of samples anti-HCV positive	41%	45%	47%	45%	49%	45%	49%	50%	50%	52%	54%	52%	55%
Number of samples anti-HCV positive	1,177	1,092	252	395	991	1,115	1,466	1,398	1,345	1,191	1,321	1,244	1,410
Total number of samples collected	2,893	2,426	536	881	2,018	2,485	2,982	2,782	2,667	2,307	2,432	2,372	2,571
Among those anti-HCV positive													
HCV RNA Prevalence						58%			57%	55%	56%	50%	50%
Number of samples HCV RNA positive						559			693	578	639	616	671
Number of samples anti-HCV positive						956			1,208	1,043	1,135	1,234	1,346
Hepatitis B vaccine uptake [*]	72%	73%		75%		77%	75%	71%	72%	75%	71%	73%	72%
Number reporting hepatitis B vaccine uptake	2,039	2,117		2,120		1,844	2,169	1,903	1,815	1,644	1,682	1,684	1,798
Total number answering question	2,828	2,893		2,816		2,408	2,886	2,662	2,532	2,198	2,353	2,296	2,493
Ever HCV VCT uptake	77%	82%		83%		84%	85%	83%	83%	86%	84%	84%	85%
Number reporting ever HCV VCT uptake	2,141	2,304		2,264		1,945	2,358	2,217	2,152	1,922	2,026	1,862	2,075
Recent [^] HCV VCT uptake	36%	40%		39%		42%	40%	34%	35%	38%	34%	36%	47%
Number reporting recent HCV VCT uptake	1,006	1,134		1,058		969	1,123	918	911	837	807	799	1,146
Total number answering question	2,774	2,805		2,726		2,318	2,790	2,687	2,581	2,232	2,398	2,222	2,434
Proportion aware of ever HCV infection [*]	49%	51%		55%		50%	54%	47%	52%	53%	52%	66%	65%
Number aware of their ever HCV infection	506	596		667		473	650	570	596	544	589	601	676
Total number answering question	1,029	1,169		1,215		937	1,195	1,211	1,140	1,034	1,142	915	1,034
Ever HIV VCT uptake	72%	75%		76%		78%	79%	76%	76%	79%	77%	78%	80%
Number reporting ever HIV VCT uptake	2,035	2,119		2,085		1,829	2,218	2,027	1,942	1,754	1,840	1,693	1,890
Total number answering question	2,808	2,827		2,761		2,357	2,812	2,671	2,548	2,219	2,387	2,172	2,372
Among those who had injected in preceding four weeks													
Level of direct sharing [†]	19%	19%		21%		17%	14%	16%	16%	17%	18%	18%	18%
Number reporting direct sharing	316	315		337		202	216	228	220	198	224	202	238
Total number answering question	1,683	1,668		1,576		1,159	1,494	1,462	1,352	1,187	1,264	1,144	1,294
Level of sharing (direct & indirect) ^{††}	39%	36%		39%		36%	35%	39%	38%	38%	40%	36%	39%
Number reporting sharing	649	609		614		415	521	570	522	453	517	411	507
Total number answering question	1,650	1,673		1,580		1,154	1,492	1,474	1,366	1,192	1,281	1,152	1,301
Proportion injecting crack	37%	31%		31%		35%	38%	39%	43%	51%	55%	53%	62%
Number reporting crack injection	630	519		489		400	566	588	596	616	713	622	816
Total number answering question	1,720	1,665		1,581		1,159	1,509	1,502	1,379	1,213	1,291	1,167	1,316
Proportion injecting into their groin	32%	36%		35%		35%	35%	39%	38%	38%	40%	39%	37%
Number reporting groin injection	549	597		546		415	527	587	527	456	526	459	494
Total number answering question	1,691	1,639		1,565		1,170	1,523	1,515	1,388	1,216	1,308	1,187	1,333
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	22%	20%		21%		18%	17%	18%	22%	21%	22%	19%	19%
Number always using a condom	180	154		163		124	146	111	122	102	95	80	80
Total number answering question	816	768		770		698	843	624	565	481	429	417	417

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 13: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region London: 2008-2018

	Year											
	2008	2009	2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	3.8%	4.1%	4.3%		3.9%	3.7%	4.5%	4.7%	2.0%	2.1%	3.9%	4.7%
Number of samples anti-HIV positive	21	24	18		11	21	17	18	7	6	13	21
Total number of samples collected	546	591	418		280	573	377	386	352	290	333	446
Anti-HBc Prevalence ^{††}	28%	32%	33%		23%	25%	29%	25%	22%	26%	25%	14%
Proportion of samples anti-HBc positive	21%	24%	28%	22%	23%	25%	29%	25%	22%	26%	25%	14%
Number of samples anti-HBc positive	114	140	84	26	64	146	110	97	78	73	82	62
Total number of samples collected	546	591	302	116	280	573	377	386	352	279	332	445
Anti-HCV Prevalence ^{††††}	57%	59%	64%		48%	59%	59%	60%	55%	63%	68%	63%
Proportion of samples anti-HCV positive	52%	54%	60%	61%	48%	59%	59%	60%	55%	63%	68%	63%
Number of samples anti-HCV positive	285	319	181	71	135	340	223	230	195	174	225	279
Total number of samples collected	546	591	302	116	280	573	377	386	352	276	332	446
Among those anti-HCV positive												
HCV RNA Prevalence					56%			63%	57%	62%	54%	41%
Number of samples HCV RNA positive					68			112	90	64	120	113
Number of samples anti-HCV positive					121			178	158	104	224	275
Hepatitis B vaccine uptake *	66%	69%	73%		70%	73%	75%	67%	71%	76%	73%	74%
Number reporting hepatitis B vaccine uptake	354	382	278		192	396	270	238	234	203	236	325
Total number answering question	533	554	382		274	541	362	357	329	267	324	440
Ever HCV VCT uptake	82%	88%	89%		83%	90%	88%	87%	87%	90%	89%	92%
Number reporting ever HCV VCT uptake	432	461	321		207	460	325	325	295	255	288	401
Recent [^] HCV VCT uptake	40%	39%	32%		37%	43%	40%	37%	36%	31%	36%	57%
Number reporting recent HCV VCT uptake	210	206	115		92	217	149	139	123	89	115	248
Total number answering question	529	524	360		249	510	368	373	339	284	322	436
Proportion aware of ever HCV infection *	65%	67%	69%		59%	65%	60%	59%	57%	66%	71%	82%
Number aware of their ever HCV infection	161	173	138		63	177	120	113	101	105	122	186
Total number answering question	249	260	201		107	271	201	192	177	159	172	228
Ever HIV VCT uptake	81%	83%	87%		77%	86%	88%	88%	84%	88%	89%	92%
Number reporting ever HIV VCT uptake	429	439	323		201	445	322	325	283	250	278	393
Total number answering question	531	532	370		261	518	366	371	336	283	314	428
Among those who had injected in preceding four weeks												
Level of direct sharing [‡]	19%	17%	25%		22%	15%	15%	15%	15%	15%	14%	14%
Number reporting direct sharing	44	41	38		21	36	22	17	18	17	17	24
Total number answering question	226	239	153		96	233	144	116	124	111	122	170
Level of sharing (direct & indirect) ^{††}	40%	34%	42%		31%	35%	36%	32%	36%	30%	25%	33%
Number reporting sharing	89	80	65		30	81	52	37	44	34	30	56
Total number answering question	225	237	155		96	231	144	117	123	113	122	172
Proportion injecting crack	50%	49%	48%		53%	54%	57%	55%	61%	68%	64%	64%
Number reporting crack injection	113	115	73		51	127	84	67	76	80	81	110
Total number answering question	228	236	153		97	234	147	122	125	117	126	171
Proportion injecting into their groin	17%	29%	35%		35%	26%	27%	31%	24%	34%	30%	34%
Number reporting groin injection	38	65	52		35	62	39	38	31	41	39	59
Total number answering question	220	228	150		99	236	147	124	127	120	128	175
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	38%	34%	26%		18%	32%	33%	35%	19%	27%	37%	28%
Number always using a condom	51	35	20		12	41	24	26	13	13	19	21
Total number answering question	134	103	77		67	127	72	75	68	48	51	76

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 14: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region East of England: 2008-2018

Sample type	Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
	Oral fluid	Oral fluid	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.84%	0.75%	0%	0.65%	0%	1.7%	0%	0%	0.44%	0.46%	1.2%
Number of samples anti-HIV positive	2	1	0	1	0	3	0	0	1	1	2
Total number of samples collected	238	134	119	153	145	176	163	241	226	219	169
Anti-HBc Prevalence ^{††}	16%	18%	10%	18%	12%	10%	13%	10%	8.0%	6.8%	7.1%
Proportion of samples anti-HBc positive	12%	13%	7.6%	18%	12%	10%	13%	10%	8.0%	6.8%	7.1%
Number of samples anti-HBc positive	29	18	9	28	17	17	22	24	18	15	12
Total number of samples collected	238	134	119	153	145	176	163	241	225	219	169
Anti-HCV Prevalence ^{†††}	34%	48%	34%	41%	37%	46%	39%	46%	43%	45%	49%
Proportion of samples anti-HCV positive	32%	44%	31%	41%	37%	46%	39%	46%	43%	45%	49%
Number of samples anti-HCV positive	75	59	37	63	53	81	63	110	96	98	82
Total number of samples collected	238	134	119	153	145	176	163	241	225	219	169
<i>Among those anti-HCV positive</i>											
HCV RNA Prevalence				50%			49%	53%	49%	53%	53%
Number of samples HCV RNA positive				24			24	42	41	51	41
Number of samples anti-HCV positive				48			49	80	84	96	78
Hepatitis B vaccine uptake [*]	73%	79%	63%	74%	74%	65%	72%	69%	65%	59%	68%
Number reporting hepatitis B vaccine uptake	171	104	75	109	106	106	103	158	143	116	115
Total number answering question	235	132	119	148	143	163	143	230	220	197	169
Ever HCV VCT uptake	77%	86%	74%	90%	71%	80%	78%	77%	79%	74%	86%
Number reporting ever HCV VCT uptake	176	112	87	134	101	137	124	176	172	146	144
Recent [^] HCV VCT uptake	36%	41%	36%	35%	23%	30%	26%	30%	32%	30%	43%
Number reporting recent HCV VCT uptake	82	54	42	52	33	52	41	69	69	59	72
Total number answering question	228	131	117	149	142	171	158	230	219	197	167
Proportion aware of ever HCV infection [*]	37%	58%	53%	57%	33%	47%	47%	49%	51%	65%	63%
Number aware of their ever HCV infection	22	31	18	31	15	32	25	39	43	49	35
Total number answering question	59	53	34	54	45	68	53	79	84	75	56
Ever HIV VCT uptake	74%	77%	70%	84%	71%	77%	74%	67%	73%	72%	85%
Number reporting ever HIV VCT uptake	172	101	81	126	100	132	114	155	159	138	137
Total number answering question	231	131	115	150	141	171	154	233	217	192	162
Among those who had injected in preceding four weeks											
Level of direct sharing [‡]	22%	27%	29%	15%	5.5%	12%	12%	16%	17%	24%	14%
Number reporting direct sharing	23	12	24	8	4	11	7	23	19	20	12
Total number answering question	106	45	83	52	73	93	60	142	115	84	87
Level of sharing (direct & indirect) ^{††}	42%	42%	45%	35%	22%	38%	31%	39%	36%	47%	33%
Number reporting sharing	46	19	37	18	16	36	19	56	41	40	28
Total number answering question	109	45	83	52	73	94	61	142	115	85	86
Proportion injecting crack	21%	24%	24%	40%	39%	38%	43%	46%	50%	53%	50%
Number reporting crack injection	23	11	20	21	28	36	26	68	58	46	43
Total number answering question	109	46	82	53	72	96	61	147	116	87	86
Proportion injecting into their groin	30%	33%	17%	32%	37%	38%	34%	36%	33%	28%	37%
Number reporting groin injection	32	15	13	17	27	38	21	52	39	25	32
Total number answering question	106	46	78	53	73	99	62	146	118	88	87
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	36%	17%	42%	26%	25%	7.7%	26%	20%	24%	6.9%	0%
Number always using a condom	27	6	16	10	11	4	8	12	9	2	0
Total number answering question	74	35	38	38	44	52	31	60	37	29	19

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years. Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 15: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region South East: 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.88%	0.76%		1.2%		1.8%	1.0%	0.46%	0%	1.8%	0%	0.35%	0.23%
Number of samples anti-HIV positive	4	4		5		6	3	1	0	5	0	1	1
Total number of samples collected	452	524		428		337	300	217	237	271	275	283	431
Anti-HBc Prevalence ^{††}	24%	18%		16%		18%	25%	18%	20%	20%	7.6%	9.2%	8.4%
Proportion of samples anti-HBc positive	18%	12%	26%	0%	16%	18%	25%	18%	20%	20%	7.6%	9.2%	8.4%
Number of samples anti-HBc positive	80	49	31	0	68	61	74	39	47	55	21	26	36
Total number of samples collected	452	407	117	14	414	337	300	217	237	270	275	283	431
Anti-HCV Prevalence ^{†††}	51%	52%		57%		54%	58%	54%	58%	58%	50%	60%	60%
Proportion of samples anti-HCV positive	46%	47%	56%	29%	57%	54%	58%	54%	58%	58%	50%	60%	60%
Number of samples anti-HCV positive	210	191	65	4	238	181	174	118	137	158	138	170	259
Total number of samples collected	452	407	117	14	414	337	300	217	237	271	275	283	431
Among those anti-HCV positive													
HCV RNA Prevalence						68%			46%	59%	61%	46%	51%
Number of samples HCV RNA positive						113			61	82	81	79	124
Number of samples anti-HCV positive						167			133	139	132	170	244
Hepatitis B vaccine uptake *	70%	71%		75%		77%	73%	74%	73%	73%	67%	71%	71%
Number reporting hepatitis B vaccine uptake	308	364		314		256	218	151	168	185	181	200	300
Total number answering question	442	512		420		332	297	204	229	255	271	282	424
Ever HCV VCT uptake	77%	81%		82%		86%	84%	88%	91%	88%	81%	83%	87%
Number reporting ever HCV VCT uptake	339	414		347		283	249	182	210	231	218	230	364
Recent [^] HCV VCT uptake	37%	37%		36%		45%	44%	44%	43%	44%	28%	40%	52%
Number reporting recent HCV VCT uptake	163	186		151		149	129	92	100	116	75	112	217
Total number answering question	438	508		425		330	295	208	232	262	270	278	420
Proportion aware of ever HCV infection *	47%	44%		53%		59%	60%	50%	50%	44%	56%	74%	64%
Number aware of their ever HCV infection	90	99		121		97	90	53	60	61	71	92	132
Total number answering question	193	225		227		165	151	106	120	138	126	125	207
Ever HIV VCT uptake	75%	79%		77%		83%	83%	81%	83%	82%	75%	75%	84%
Number reporting ever HIV VCT uptake	332	401		330		276	244	171	191	209	200	201	345
Total number answering question	445	508		427		331	294	211	230	256	266	268	410
Among those who had injected in preceding four weeks													
Level of direct sharing [‡]	21%	26%		21%		21%	14%	14%	18%	21%	24%	18%	19%
Number reporting direct sharing	67	85		59		47	28	19	27	35	36	25	48
Total number answering question	315	328		277		220	201	137	152	165	148	140	250
Level of sharing (direct & indirect) ^{††}	48%	47%		44%		37%	34%	41%	37%	45%	50%	37%	41%
Number reporting sharing	154	154		125		81	67	57	57	74	74	52	104
Total number answering question	318	329		282		219	199	138	154	166	149	140	251
Proportion injecting crack	49%	40%		43%		46%	46%	54%	65%	60%	68%	73%	74%
Number reporting crack injection	155	132		121		102	92	75	102	100	102	102	187
Total number answering question	318	329		282		222	199	140	157	166	149	140	253
Proportion injecting into their groin	33%	38%		36%		33%	28%	29%	37%	37%	36%	45%	34%
Number reporting groin injection	104	122		101		73	56	41	57	63	54	64	86
Total number answering question	312	325		283		223	202	139	155	169	150	143	254
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	17%	25%		15%		21%	12%	10%	15%	18%	9.3%	11%	14%
Number always using a condom	24	40		20		20	11	4	9	10	5	8	11
Total number answering question	139	159		136		97	93	40	61	57	54	70	78

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 16: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region South West: 2008-2018

Sample type	Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
	Oral fluid	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.44%	0%	0.34%	0.31%	0.52%	0%	0%	1.5%	0.45%	0%	0.51%
Number of samples anti-HIV positive	1	0	1	1	2	0	0	4	1	0	2
Total number of samples collected	227	260	294	322	383	298	267	259	224	114	390
Anti-HBc Prevalence ^{††}	16%	16%	7.5%	11%	13%	15%	11%	11%	14%	8.8%	10%
Proportion of samples anti-HBc positive	12%	12%	7.5%	11%	13%	15%	11%	11%	14%	8.8%	10%
Number of samples anti-HBc positive	28	32	22	36	48	44	29	29	32	10	39
Total number of samples collected	227	260	294	322	383	298	267	259	224	114	390
Anti-HCV Prevalence ^{†††}	36%	40%	38%	40%	35%	40%	51%	47%	67%	54%	54%
Proportion of samples anti-HCV positive	33%	37%	38%	40%	35%	40%	51%	47%	67%	54%	54%
Number of samples anti-HCV positive	75	96	111	128	135	118	136	123	150	62	209
Total number of samples collected	227	260	294	322	383	298	267	259	224	114	390
<i>Among those anti-HCV positive</i>											
HCV RNA Prevalence				54%			58%	52%	61%	40%	55%
Number of samples HCV RNA positive				65			76	60	89	25	112
Number of samples anti-HCV positive				121			130	115	147	62	202
Hepatitis B vaccine uptake [*]	71%	64%	79%	72%	71%	65%	70%	75%	71%	78%	72%
Number reporting hepatitis B vaccine uptake	159	167	224	228	258	188	179	187	151	88	262
Total number answering question	223	259	285	315	365	288	255	250	214	113	365
Ever HCV VCT uptake	72%	81%	84%	82%	83%	83%	87%	86%	88%	84%	90%
Number reporting ever HCV VCT uptake	160	204	231	247	294	242	227	219	194	95	315
Recent [^] HCV VCT uptake	25%	43%	49%	44%	39%	32%	41%	40%	45%	43%	46%
Number reporting recent HCV VCT uptake	55	109	134	133	140	93	106	102	98	49	161
Total number answering question	222	252	274	302	355	292	261	254	220	113	351
Proportion aware of ever HCV infection [*]	37%	52%	57%	53%	47%	43%	57%	55%	56%	71%	62%
Number aware of their ever HCV infection	25	45	54	57	50	41	66	58	71	35	85
Total number answering question	67	87	95	107	106	96	115	106	127	49	137
Ever HIV VCT uptake	70%	74%	79%	76%	82%	80%	78%	83%	80%	78%	77%
Number reporting ever HIV VCT uptake	156	186	224	238	293	228	204	211	178	87	266
Total number answering question	224	252	282	312	359	286	260	254	222	112	344
Among those who had injected in preceding four weeks											
Level of direct sharing [‡]	20%	20%	31%	23%	20%	20%	23%	22%	22%	29%	22%
Number reporting direct sharing	30	33	48	39	36	29	38	32	41	20	47
Total number answering question	148	165	154	172	180	148	167	145	185	69	211
Level of sharing (direct & indirect) ^{††}	38%	39%	51%	47%	46%	54%	55%	51%	49%	48%	42%
Number reporting sharing	56	65	78	80	83	82	93	75	92	33	88
Total number answering question	149	168	154	170	182	153	168	148	189	69	212
Proportion injecting crack	36%	31%	25%	34%	38%	35%	64%	66%	82%	73%	72%
Number reporting crack injection	55	51	39	58	68	54	107	101	155	52	152
Total number answering question	151	167	156	169	180	156	167	152	189	71	211
Proportion injecting into their groin	37%	34%	37%	34%	33%	39%	36%	42%	47%	41%	40%
Number reporting groin injection	54	56	56	58	60	61	60	64	90	29	85
Total number answering question	147	165	153	171	184	155	165	152	192	70	214
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	20%	10%	20%	17%	11%	18%	16%	21%	20%	17%	16%
Number always using a condom	13	7	19	18	14	13	12	13	9	5	9
Total number answering question	64	68	95	109	130	73	75	62	45	30	56

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 17: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region West Midlands: 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.43%	0%		0%		1.4%	1.8%	1.5%	0%	0%	1.1%	0.36%	0.85%
Number of samples anti-HIV positive	1	0		0		4	4	6	0	0	3	1	2
Total number of samples collected	231	315		291		276	228	412	291	154	273	280	234
Anti-HBc Prevalence ^{††}	5.2%	7.7%		5.6%		7.2%	7.0%	10%	5.5%	2.6%	4.0%	3.2%	3.4%
Proportion of samples anti-HBc positive	3.9%	7.7%	2.8%	7.7%	4.6%	7.2%	7.0%	10%	5.5%	2.6%	4.0%	3.2%	3.4%
Number of samples anti-HBc positive	9	16	3	4	11	20	16	42	16	4	11	9	8
Total number of samples collected	231	207	108	52	239	276	228	412	291	154	273	280	234
Anti-HCV Prevalence ^{†††}	29%	36%		28%		33%	37%	42%	36%	26%	39%	35%	44%
Proportion of samples anti-HCV positive	26%	34%	33%	42%	24%	33%	37%	42%	36%	26%	39%	35%	44%
Number of samples anti-HCV positive	61	70	36	22	57	90	84	174	104	40	99	97	104
Total number of samples collected	231	207	108	52	239	276	228	412	291	154	254	280	234
Among those anti-HCV positive													
HCV RNA Prevalence						51%			64%	58%	54%	37%	53%
Number of samples HCV RNA positive						42			67	23	50	36	52
Number of samples anti-HCV positive						83			104	40	93	97	99
Hepatitis B vaccine uptake *	59%	67%		65%		76%	71%	64%	69%	71%	62%	62%	60%
Number reporting hepatitis B vaccine uptake	130	209		187		204	160	257	195	108	163	168	129
Total number answering question	222	312		287		270	224	401	282	153	263	271	215
Ever HCV VCT uptake	65%	71%		64%		75%	80%	78%	80%	87%	81%	77%	75%
Number reporting ever HCV VCT uptake	140	217		181		199	175	315	227	131	217	209	162
Recent^ HCV VCT uptake	28%	37%		25%		31%	30%	26%	32%	45%	33%	34%	45%
Number reporting recent HCV VCT uptake	61	114		71		82	65	106	90	68	89	91	97
Total number answering question	216	306		284		267	220	406	283	151	269	270	217
Proportion aware of ever HCV infection *	38%	46%		44%		29%	53%	46%	55%	53%	40%	52%	57%
Number aware of their ever HCV infection	21	45		32		22	38	68	45	18	33	37	43
Total number answering question	56	97		73		77	72	149	82	34	83	71	76
Ever HIV VCT uptake	66%	69%		61%		73%	75%	71%	74%	78%	77%	74%	75%
Number reporting ever HIV VCT uptake	149	213		174		196	167	284	208	117	208	195	160
Total number answering question	225	309		285		269	223	401	280	150	270	262	212
Among those who had injected in preceding four weeks													
Level of direct sharing [‡]	13%	16%		12%		13%	11%	15%	15%	4.0%	16%	16%	12%
Number reporting direct sharing	21	32		16		13	12	36	23	3	23	22	17
Total number answering question	157	194		131		97	106	233	151	75	141	135	137
Level of sharing (direct & indirect) ^{††}	30%	31%		25%		32%	28%	32%	37%	25%	35%	33%	34%
Number reporting sharing	47	60		33		31	29	74	57	19	49	45	46
Total number answering question	157	194		131		97	105	234	153	75	140	135	137
Proportion injecting crack	35%	33%		24%		34%	54%	45%	35%	33%	41%	54%	67%
Number reporting crack injection	57	64		31		32	58	107	54	25	56	73	94
Total number answering question	163	193		130		95	107	237	155	76	138	134	140
Proportion injecting into their groin	34%	40%		35%		32%	35%	38%	31%	32%	35%	45%	31%
Number reporting groin injection	56	77		46		30	38	92	48	24	50	61	44
Total number answering question	164	192		130		95	110	244	157	76	141	135	140
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	17%	24%		22%		23%	14%	21%	27%	27%	28%	20%	13%
Number always using a condom	11	21		17		16	9	19	16	8	13	8	6
Total number answering question	64	89		78		71	65	92	60	30	46	40	45

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 18: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region North West: 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	2.6%	2.3%		1.8%		1.8%	2.2%	0%	0%	0.48%	0.61%	0.32%	0.28%
Number of samples anti-HIV positive	11	10		8		7	9	0	0	2	3	1	1
Total number of samples collected	427	428		434		397	409	379	383	414	495	316	354
Anti-HBc Prevalence ^{††}	29%	25%		26%		28%	27%	31%	27%	23%	21%	22%	15%
Proportion of samples anti-HBc positive	22%	18%	26%	24%	25%	28%	27%	31%	27%	23%	21%	22%	15%
Number of samples anti-HBc positive	94	72	9	20	88	110	109	110	103	97	103	71	53
Total number of samples collected	426	393	35	84	350	397	409	356	383	414	493	316	354
Anti-HCV Prevalence ^{†††}	63%	62%		65%		60%	64%	68%	66%	68%	67%	60%	63%
Proportion of samples anti-HCV positive	58%	56%	63%	68%	63%	60%	64%	68%	66%	68%	67%	60%	63%
Number of samples anti-HCV positive	246	222	22	57	219	239	263	258	251	281	333	190	223
Total number of samples collected	427	393	35	84	350	397	409	379	383	414	495	316	354
Among those anti-HCV positive													
HCV RNA Prevalence						63%			55%	54%	54%	53%	51%
Number of samples HCV RNA positive						105			123	135	154	100	109
Number of samples anti-HCV positive						167			224	251	287	189	212
Hepatitis B vaccine uptake *	75%	74%		75%		81%	77%	71%	70%	81%	77%	82%	73%
Number reporting hepatitis B vaccine uptake	311	313		320		316	310	258	256	327	360	252	251
Total number answering question	417	423		429		389	401	362	367	402	469	308	344
Ever HCV VCT uptake	81%	83%		86%		90%	86%	78%	82%	90%	87%	88%	84%
Number reporting ever HCV VCT uptake	334	346		356		343	332	287	302	364	415	264	278
Recent ^ HCV VCT uptake	36%	38%		43%		49%	45%	31%	28%	36%	33%	36%	40%
Number reporting recent HCV VCT uptake	146	157		178		186	172	114	105	146	158	109	132
Total number answering question	411	415		414		382	384	366	369	404	479	299	332
Proportion aware of ever HCV infection *	49%	52%		54%		56%	56%	44%	57%	52%	49%	69%	63%
Number aware of their ever HCV infection	103	114		140		111	110	98	123	129	138	95	100
Total number answering question	210	218		258		199	197	223	215	250	281	138	159
Ever HIV VCT uptake	74%	72%		79%		82%	80%	66%	70%	81%	74%	73%	69%
Number reporting ever HIV VCT uptake	306	299		332		316	311	238	256	324	352	213	225
Total number answering question	414	415		420		384	389	359	364	399	478	292	324
Among those who had injected in preceding four weeks													
Level of direct sharing [‡]	16%	13%		15%		11%	12%	14%	14%	15%	11%	17%	18%
Number reporting direct sharing	36	30		26		18	20	21	22	27	24	24	27
Total number answering question	226	228		179		162	161	145	156	181	214	143	153
Level of sharing (direct & indirect) ^{††}	39%	28%		29%		29%	30%	34%	38%	34%	39%	39%	38%
Number reporting sharing	89	65		52		47	49	50	60	61	86	57	58
Total number answering question	227	229		179		160	161	146	157	180	220	148	154
Proportion injecting crack	56%	36%		28%		31%	32%	48%	50%	54%	54%	47%	61%
Number reporting crack injection	127	80		51		49	53	72	80	98	122	70	97
Total number answering question	226	224		179		160	165	150	159	183	224	150	159
Proportion injecting into their groin	41%	46%		40%		44%	38%	45%	42%	46%	42%	37%	44%
Number reporting groin injection	93	105		71		71	64	67	67	84	94	56	72
Total number answering question	226	226		179		162	168	150	159	181	226	153	163
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	21%	21%		26%		26%	27%	15%	28%	26%	24%	19%	19%
Number always using a condom	20	22		26		25	24	11	17	18	17	10	8
Total number answering question	94	106		99		98	90	74	60	69	71	53	43

* Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 19: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region Yorkshire & Humber: 2008-2018

Sample type	Year											
	2008	2009	2010		2011	2012	2013	2014	2015	2016	2017	2018
	Oral fluid	Oral fluid	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0%		0%		0%	0%	0.29%	0.25%	0%	0.37%	0%	0%
Number of samples anti-HIV positive	0		0		0	0	1	1	0	1	0	0
Total number of samples collected	261		402		297	299	341	396	228	270	235	165
Anti-HBc Prevalence ^{††}	6.6%		16%		13%	8.7%	11%	8.6%	4.0%	12%	9.4%	7.9%
Proportion of samples anti-HBc positive	5.0%		4.6%	19%	13%	8.7%	11%	8.6%	4.0%	12%	9.4%	7.9%
Number of samples anti-HBc positive	13		4	59	38	26	38	34	9	32	22	13
Total number of samples collected	261		87	315	297	299	341	396	227	270	235	165
Anti-HCV Prevalence ^{†††}	42%		52%		47%	57%	50%	52%	48%	57%	59%	53%
Proportion of samples anti-HCV positive	39%		51%	52%	47%	57%	50%	52%	48%	57%	59%	53%
Number of samples anti-HCV positive	102		44	163	140	171	172	207	110	153	138	87
Total number of samples collected	261		87	315	297	299	341	396	228	270	235	165
<i>Among those anti-HCV positive</i>												
HCV RNA Prevalence					65%			67%	56%	56%	52%	44%
Number of samples HCV RNA positive					81			125	57	81	71	37
Number of samples anti-HCV positive					124			187	102	144	136	84
Hepatitis B vaccine uptake *	80%		76%		78%	83%	77%	78%	78%	79%	78%	80%
Number reporting hepatitis B vaccine uptake	207		300		215	237	257	292	164	194	173	131
Total number answering question	258		394		276	286	332	374	211	245	221	164
Ever HCV VCT uptake	77%		86%		83%	85%	83%	83%	82%	88%	85%	78%
Number reporting ever HCV VCT uptake	190		323		213	245	273	312	176	222	192	123
Recent [†] HCV VCT uptake	32%		39%		41%	40%	38%	39%	35%	34%	31%	39%
Number reporting recent HCV VCT uptake	79		146		104	114	123	149	76	85	70	62
Total number answering question	247		376		256	288	328	378	215	253	226	157
Proportion aware of ever HCV infection *	56%		51%		46%	57%	49%	49%	63%	55%	65%	50%
Number aware of their ever HCV infection	45		89		51	88	71	85	60	72	70	31
Total number answering question	80		173		111	154	146	173	96	130	107	62
Ever HIV VCT uptake	59%		68%		72%	76%	72%	73%	75%	77%	78%	74%
Number reporting ever HIV VCT uptake	145		259		188	214	238	273	164	192	166	112
Total number answering question	245		379		262	282	329	375	219	248	213	152
Among those who had injected in preceding four weeks												
Level of direct sharing [‡]	18%		23%		12%	17%	14%	13%	15%	19%	15%	15%
Number reporting direct sharing	16		54		13	27	25	23	17	22	18	10
Total number answering question	88		230		107	157	179	183	115	114	124	65
Level of sharing (direct & indirect) ^{††}	34%		45%		38%	40%	41%	36%	44%	43%	34%	49%
Number reporting sharing	30		102		41	63	73	67	51	49	43	33
Total number answering question	88		225		107	157	179	188	117	115	127	67
Proportion injecting crack	51%		33%		44%	41%	43%	35%	56%	61%	72%	73%
Number reporting crack injection	45		75		47	65	78	67	67	70	92	52
Total number answering question	89		225		107	160	183	189	119	114	127	71
Proportion injecting into their groin	36%		42%		45%	45%	49%	41%	48%	43%	56%	40%
Number reporting groin injection	32		96		48	71	92	78	57	49	72	29
Total number answering question	89		226		107	159	187	190	119	115	129	72
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	12%		21%		15%	15%	16%	17%	26%	19%	13%	29%
Number always using a condom	8		21		13	12	13	11	12	9	4	8
Total number answering question	67		100		85	82	80	66	47	48	30	28

* Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years. Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 20: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region East Midlands: 2008-2018

	Year											
	2008	2009		2010	2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.86%	1.4%		0.87%	0.97%	1.1%	0.93%	2.5%	2.2%	2.8%	1.2%	0%
Number of samples anti-HIV positive	3	4		2	2	3	3	8	5	6	4	0
Total number of samples collected	349	289		229	206	281	322	319	231	217	345	256
Anti-HBc Prevalence ^{††}	8.0%	4.6%		14%	8.3%	12%	11%	12%	13%	7.9%	9.0%	5.1%
Proportion of samples anti-HBc positive	6.0%	2.8%	5.5%	14%	8.3%	12%	11%	12%	13%	7.9%	9.0%	5.1%
Number of samples anti-HBc positive	21	4	8	33	17	33	37	38	31	17	31	13
Total number of samples collected	349	144	145	229	206	281	322	319	231	216	345	256
Anti-HCV Prevalence ^{†††}	31%	44%		46%	33%	44%	49%	47%	51%	48%	50%	43%
Proportion of samples anti-HCV positive	29%	33%	52%	46%	33%	44%	49%	47%	51%	48%	50%	43%
Number of samples anti-HCV positive	100	47	76	105	68	125	159	151	117	104	172	109
Total number of samples collected	349	144	145	229	206	281	322	319	231	216	345	256
Among those anti-HCV positive												
HCV RNA Prevalence					52%			56%	60%	58%	52%	49%
Number of samples HCV RNA positive					33			83	64	53	89	49
Number of samples anti-HCV positive					64			148	106	92	171	100
Hepatitis B vaccine uptake *	78%	79%		80%	81%	79%	77%	75%	74%	73%	77%	77%
Number reporting hepatitis B vaccine uptake	266	226		181	162	216	232	231	163	153	256	190
Total number answering question	342	287		226	200	274	302	306	219	211	334	246
Ever HCV VCT uptake	80%	85%		88%	84%	86%	85%	86%	90%	87%	86%	87%
Number reporting ever HCV VCT uptake	265	235		188	161	224	256	267	204	182	240	199
Recent ^ HCV VCT uptake	46%	52%		47%	44%	39%	33%	37%	35%	36%	34%	45%
Number reporting recent HCV VCT uptake	154	144		100	84	102	101	114	80	76	94	103
Total number answering question	333	276		213	192	260	302	310	226	209	280	230
Proportion aware of ever HCV infection *	35%	38%		52%	37%	46%	41%	47%	59%	42%	56%	62%
Number aware of their ever HCV infection	30	43		48	21	47	55	63	62	37	57	42
Total number answering question	85	112		92	57	102	134	135	105	88	101	68
Ever HIV VCT uptake	70%	71%		69%	70%	72%	75%	75%	81%	82%	80%	78%
Number reporting ever HIV VCT uptake	236	199		148	137	191	227	225	177	171	225	170
Total number answering question	337	281		214	195	264	301	299	219	208	280	218
Among those who had injected in preceding four weeks												
Level of direct sharing [‡]	19%	14%		18%	15%	11%	13%	14%	19%	11%	15%	29%
Number reporting direct sharing	48	29		29	20	19	30	33	27	11	23	37
Total number answering question	258	207		162	134	173	225	230	143	99	151	127
Level of sharing (direct & indirect) ^{††}	40%	40%		33%	31%	34%	35%	32%	31%	25%	33%	51%
Number reporting sharing	88	83		53	42	58	79	73	44	25	50	65
Total number answering question	221	207		162	134	173	227	231	144	100	151	128
Proportion injecting crack	23%	18%		36%	27%	34%	28%	37%	49%	57%	55%	56%
Number reporting crack injection	62	38		59	37	61	64	85	73	57	84	73
Total number answering question	268	206		166	136	177	228	230	148	100	154	131
Proportion injecting into their groin	36%	40%		37%	31%	43%	39%	44%	29%	44%	30%	41%
Number reporting groin injection	95	81		60	43	77	89	104	42	44	47	54
Total number answering question	261	201		164	138	178	229	235	147	101	159	132
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	15%	10%		7.9%	8.9%	8.8%	18%	23%	22%	29%	16%	22%
Number always using a condom	16	7		5	5	7	13	19	11	10	9	10
Total number answering question	109	70		63	56	80	73	81	49	34	57	45

* Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 21: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; PHE Region North East: 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	0.40%	0.91%		0.35%		0%	0.27%	0.38%	0%	0%	0%	0%	0.79%
Number of samples anti-HIV positive	1	3		1		0	1	1	0	0	0	0	1
Total number of samples collected	252	331		284		217	364	260	225	157	199	248	126
Anti-HBc Prevalence ^{††}	11%	10%		11%		10%	9.1%	10%	7.6%	5.7%	6.6%	6.9%	3.2%
Proportion of samples anti-HBc positive	7.9%	9.0%	6.1%	9.4%	3.3%	10%	9.1%	10%	7.6%	5.7%	6.6%	6.9%	3.2%
Number of samples anti-HBc positive	20	18	8	21	2	22	33	25	17	9	13	17	4
Total number of samples collected	252	200	131	223	61	217	364	260	225	157	198	248	126
Anti-HCV Prevalence ^{†††}	25%	33%		29%		33%	33%	37%	29%	36%	38%	37%	46%
Proportion of samples anti-HCV positive	23%	26%	40%	22%	44%	33%	33%	37%	29%	36%	38%	37%	46%
Number of samples anti-HCV positive	59	52	53	50	27	71	121	95	66	57	74	92	58
Total number of samples collected	252	200	131	223	61	217	364	260	225	157	197	248	126
Among those anti-HCV positive													
HCV RNA Prevalence						46%			40%	48%	50%	51%	65%
Number of samples HCV RNA positive						28			22	25	26	45	34
Number of samples anti-HCV positive						61			55	52	52	89	52
Hepatitis B vaccine uptake *	83%	87%		88%		79%	75%	74%	70%	79%	69%	79%	75%
Number reporting hepatitis B vaccine uptake	203	282		241		162	268	184	153	118	134	195	95
Total number answering question	246	324		274		204	355	248	219	149	193	246	126
Ever HCV VCT uptake	75%	79%		87%		83%	83%	81%	73%	83%	77%	84%	72%
Number reporting ever HCV VCT uptake	178	242		230		159	278	200	158	126	151	198	89
Recent [^] HCV VCT uptake	39%	42%		46%		46%	45%	36%	31%	38%	35%	42%	44%
Number reporting recent HCV VCT uptake	91	129		121		87	151	88	67	57	68	100	54
Total number answering question	236	307		263		191	336	246	217	151	195	237	124
Proportion aware of ever HCV infection [*]	43%	34%		44%		33%	36%	36%	29%	33%	30%	57%	54%
Number aware of their ever HCV infection	23	32		27		20	35	32	16	16	19	44	22
Total number answering question	54	93		62		60	97	88	55	49	64	77	41
Ever HIV VCT uptake	68%	72%		80%		78%	74%	76%	68%	75%	67%	79%	67%
Number reporting ever HIV VCT uptake	162	229		214		151	253	187	146	114	130	190	82
Total number answering question	238	317		269		193	342	247	215	153	195	239	122
Among those who had injected in preceding four weeks													
Level of direct sharing [‡]	19%	21%		21%		19%	16%	22%	22%	16%	23%	19%	17%
Number reporting direct sharing	36	48		43		23	34	35	30	16	31	33	16
Total number answering question	189	232		207		119	210	158	137	97	137	176	94
Level of sharing (direct & indirect) ^{††}	31%	32%		33%		38%	36%	42%	43%	30%	48%	35%	31%
Number reporting sharing	57	76		69		45	75	67	59	29	67	61	29
Total number answering question	186	234		209		119	211	159	137	97	140	175	94
Proportion injecting crack	4.5%	5.1%		9.6%		2.5%	6.5%	11%	5.8%	8.2%	9.0%	12%	8.5%
Number reporting crack injection	9	12		20		3	14	18	8	8	13	22	8
Total number answering question	198	234		208		120	215	165	139	97	144	178	94
Proportion injecting into their groin	31%	27%		25%		33%	34%	41%	38%	39%	45%	36%	34%
Number reporting groin injection	60	61		51		40	72	68	54	39	65	66	33
Total number answering question	196	226		202		122	213	165	141	99	145	182	96
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	15%	10%		23%		6.5%	13%	15%	7.1%	13%	22%	26%	26%
Number always using a condom	14	12		19		5	17	10	4	5	10	15	7
Total number answering question	93	116		84		77	132	68	56	39	46	57	27

* Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 22: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; Wales: 2008-2018

Sample type	Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Anti-HIV Prevalence [†]	1.8%	0.57%	0%	1.1%	0%	0.50%	1.1%	0.77%	1.4%	0.94%	1.8%
Number of samples anti-HIV positive	3	1	0	2	0	1	3	2	3	2	3
Total number of samples collected	164	174	196	175	236	201	270	261	217	212	169
Anti-HBc Prevalence ^{††}	12%	4.6%	5.4%	11%	10%	12%	11%	11%	10%	7.5%	11%
Proportion of samples anti-HBc positive	9.1%	3.4%	4.1%	11%	10%	12%	11%	11%	10%	7.5%	11%
Number of samples anti-HBc positive	15	6	8	19	24	25	30	29	22	16	18
Total number of samples collected	164	174	196	175	236	201	270	261	217	212	169
Anti-HCV Prevalence ^{††††}	31%	32%	26%	39%	33%	47%	50%	53%	52%	50%	56%
Proportion of samples anti-HCV positive	29%	29%	24%	39%	33%	47%	50%	53%	52%	50%	56%
Number of samples anti-HCV positive	47	51	47	68	77	94	136	138	113	106	94
Total number of samples collected	164	174	196	175	236	201	270	261	217	212	169
<i>Among those anti-HCV positive</i>											
HCV RNA Prevalence				68%			57%	60%	53%	41%	45%
Number of samples HCV RNA positive				38			70	72	55	42	40
Number of samples anti-HCV positive				56			122	121	103	102	89
Hepatitis B vaccine uptake *	60%	72%	64%	79%	77%	74%	76%	74%	67%	76%	70%
Number reporting hepatitis B vaccine uptake	98	120	125	136	178	144	195	187	138	158	116
Total number answering question	163	167	194	173	231	195	256	253	206	208	166
Ever HCV VCT uptake	74%	76%	62%	86%	85%	84%	86%	82%	82%	82%	81%
Number reporting ever HCV VCT uptake	117	125	115	141	188	168	228	211	172	169	136
Recent[^] HCV VCT uptake	32%	41%	35%	38%	42%	46%	43%	41%	39%	32%	43%
Number reporting recent HCV VCT uptake	50	68	65	63	93	92	114	107	82	66	71
Total number answering question	158	164	185	164	222	199	265	258	209	207	167
Proportion aware of ever HCV infection *	51%	45%	34%	56%	42%	38%	48%	47%	56%	63%	51%
Number aware of their ever HCV infection	20	19	12	32	26	33	59	53	58	50	39
Total number answering question	39	42	35	57	62	86	123	112	103	79	76
Ever HIV VCT uptake	65%	72%	63%	77%	81%	73%	79%	75%	80%	76%	78%
Number reporting ever HIV VCT uptake	101	122	116	130	185	143	206	191	169	154	127
Total number answering question	155	170	185	168	228	196	260	254	210	203	163
Among those who had injected in preceding four weeks											
Level of direct sharing [‡]	28%	17%	20%	11%	10%	21%	22%	13%	11%	20%	20%
Number reporting direct sharing	19	18	16	12	14	26	34	23	15	24	21
Total number answering question	68	103	81	111	134	125	158	183	142	122	107
Level of sharing (direct & indirect) ^{††}	50%	32%	41%	30%	25%	44%	41%	42%	36%	35%	36%
Number reporting sharing	34	32	33	33	34	56	66	78	51	44	39
Total number answering question	68	100	81	111	134	126	162	186	142	126	107
Proportion injecting crack	13%	6.8%	8.6%	19%	22%	21%	18%	24%	37%	36%	43%
Number reporting crack injection	9	7	7	21	29	26	30	43	53	45	46
Total number answering question	71	103	81	108	133	124	165	179	143	126	106
Proportion injecting into their groin	26%	8.8%	15%	32%	33%	29%	39%	40%	39%	37%	41%
Number reporting groin injection	18	9	12	36	44	37	64	75	57	47	44
Total number answering question	70	102	80	111	135	129	165	187	145	128	108
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	11%	18%	27%	28%	7.0%	20%	21%	20%	24%	16%	12%
Number always using a condom	4	8	16	12	3	10	14	14	12	8	4
Total number answering question	37	45	59	43	43	50	67	71	51	49	34

* Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 23: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use; Northern Ireland: 2008-2018

Sample type	Year										
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Anti-HIV Prevalence [†]	2.6%	1.3%	0%	0.56%	0%	0.62%	0.65%	0.65%	0%	0%	1.2%
Number of samples anti-HIV positive	4	2	0	1	0	1	1	1	0	0	1
Total number of samples collected	152	153	193	178	171	161	154	153	126	71	86
Anti-HBc Prevalence ^{††}	7.1%	8.7%	11%	13%	5.9%	6.2%	5.8%	7.2%	5.6%	2.8%	0%
Proportion of samples anti-HBc positive	5.3%	6.5%	11%	13%	5.9%	6.2%	5.8%	7.2%	5.6%	2.8%	0%
Number of samples anti-HBc positive	8	10	21	23	10	10	9	11	7	2	0
Total number of samples collected	151	153	193	178	170	161	154	152	125	71	86
Anti-HCV Prevalence ^{†††}	36%	28%	31%	29%	34%	32%	23%	27%	22%	23%	22%
Proportion of samples anti-HCV positive	33%	26%	31%	29%	34%	32%	23%	27%	22%	23%	22%
Number of samples anti-HCV positive	50	40	60	51	58	51	36	42	28	16	19
Total number of samples collected	152	153	193	178	171	161	154	153	125	71	86
<i>Among those anti-HCV positive</i>											
HCV RNA Prevalence				36%			47%	54%	45%	38%	39%
Number of samples HCV RNA positive				15			15	22	10	6	7
Number of samples anti-HCV positive				42			32	41	22	16	18
Hepatitis B vaccine uptake [*]	82%	80%	73%	68%	68%	75%	78%	84%	82%	81%	78%
Number reporting hepatitis B vaccine uptake	122	115	138	114	116	116	116	121	101	55	66
Total number answering question	149	144	189	167	170	154	148	144	123	68	85
Ever HCV VCT uptake	96%	92%	90%	90%	88%	91%	89%	95%	89%	91%	87%
Number reporting ever HCV VCT uptake	142	131	171	143	138	139	135	140	109	60	74
Recent [^] HCV VCT uptake	51%	51%	40%	37%	36%	29%	35%	47%	29%	33%	42%
Number reporting recent HCV VCT uptake	76	73	76	59	56	44	53	70	36	22	36
Total number answering question	148	143	190	159	157	153	151	148	123	66	85
Proportion aware of ever HCV infection [*]	66%	52%	60%	61%	53%	55%	68%	58%	62%	73%	
Number aware of their ever HCV infection	29	16	32	25	27	26	23	22	16	22	
Total number answering question	44	31	53	41	51	47	34	38	26	30	
Ever HIV VCT uptake	84%	92%	89%	90%	87%	90%	91%	93%	88%	88%	
Number reporting ever HIV VCT uptake	125	135	167	146	138	136	137	136	107	61	71
Total number answering question	148	146	188	162	159	151	150	147	121	69	81
Among those who had injected in preceding four weeks											
Level of direct sharing [‡]	17%	14%	23%	29%	19%	31%	17%	17%	8.3%	21%	
Number reporting direct sharing	8	6	10	10	6	11	5	6	2	7	
Total number answering question	47	43	44	35	32	35	30	36	24	33	
Level of sharing (direct & indirect) ^{††}	36%	36%	36%	34%	35%	42%	30%	31%	13%	33%	
Number reporting sharing	17	15	16	12	11	15	9	11	3	11	
Total number answering question	47	42	44	35	31	36	30	36	24	33	
Proportion injecting crack	2.2%	0%	6.8%	0%	3.3%	2.7%	3.6%	0%	0%	6.3%	
Number reporting crack injection	1	0	3	0	1	1	1	0	0	2	
Total number answering question	46	40	44	34	30	37	28	36	24	32	
Proportion injecting into their groin	26%	30%	21%	24%	41%	26%	23%	46%	60%	42%	
Number reporting groin injection	12	12	9	8	13	10	7	17	15	14	
Total number answering question	47	40	42	34	32	38	31	37	25	33	
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	28%	19%	35%	39%	11%	23%	28%	33%	25%	29%	
Number always using a condom	10	6	17	14	4	7	7	8	7	13	
Total number answering question	36	31	49	36	38	31	25	24	28	45	

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years. Data are provided in paired years where numbers for individual years are small.

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 24: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of diagnostic testing for hepatitis C & HIV, injecting risks and condom use in those who began injecting in the last three years (recent initiates): 2008-2018

	Year												
	2008	2009		2010		2011	2012	2013	2014	2015	2016	2017	2018
Sample type	Oral fluid	Oral fluid	DBS	Oral fluid	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence [†]	1.3%	0.71%		0.50%		0.37%	1.0%	1.0%	0.41%	2.6%	1.0%	0%	0.46%
Number of samples anti-HIV positive	5	3		2		1	4	3	1	6	2	0	1
Total number of samples collected	391	421		403		269	382	304	243	229	194	184	219
Anti-HBc Prevalence ^{††}	3.1%	7.1%		7.2%		5.9%	6.5%	5.6%	2.1%	3.9%	3.1%	2.2%	2.3%
Proportion of samples anti-HBc positive	2.3%	6.1%	2.6%	7.7%	5.3%	5.9%	6.5%	5.6%	2.1%	3.9%	3.1%	2.2%	2.3%
Number of samples anti-HBc positive	9	21	2	12	13	16	25	17	5	9	6	4	5
Total number of samples collected	391	345	76	156	247	269	382	303	243	228	194	184	219
Anti-HCV Prevalence ^{†††}	24%	24%		23%		20%	24%	24%	19%	24%	27%	22%	31%
Proportion of samples anti-HCV positive	22%	22%	24%	20%	23%	20%	24%	24%	19%	24%	27%	22%	31%
Number of samples anti-HCV positive	87	77	18	31	57	53	90	74	47	55	53	40	68
Total number of samples collected	391	345	76	156	247	269	382	304	243	229	193	184	219
Among those anti-HCV positive													
HCV RNA Prevalence						59%			44%	45%	47%	54%	59%
Number of samples HCV RNA positive						27			20	21	22	21	40
Number of samples anti-HCV positive						46			45	47	47	39	68
Hepatitis B vaccine uptake [*]	62%	68%		64%		67%	65%	62%	62%	65%	54%	57%	50%
Number reporting hepatitis B vaccine uptake	238	284		257		178	244	181	144	146	100	103	106
Total number answering question	383	420		400		266	377	294	231	223	186	182	213
Ever HCV VCT uptake	62%	69%		66%		73%	71%	67%	71%	73%	65%	59%	71%
Number reporting ever HCV VCT uptake	232	276		255		185	255	198	168	163	123	101	151
Recent [^] HCV VCT uptake	38%	43%		39%		46%	44%	38%	38%	48%	35%	33%	49%
Number reporting recent HCV VCT uptake	142	171		150		117	159	111	90	107	66	56	103
Total number answering question	376	402		386		253	359	296	238	223	189	171	212
Proportion aware of ever HCV infection [*]	30%	31%		38%		46%	41%	20%	38%	39%	22%	39%	50%
Number aware of their ever HCV infection	22	26		28		21	31	13	15	17	10	12	28
Total number answering question	73	84		73		46	76	65	39	44	45	31	56
Ever HIV VCT uptake	60%	64%		61%		64%	69%	65%	68%	68%	62%	65%	71%
Number reporting ever HIV VCT uptake	228	263		236		168	255	195	161	153	118	112	145
Total number answering question	380	408		388		261	369	298	238	224	190	171	204
Among those who had injected in preceding four weeks													
Level of direct sharing [‡]	17%	17%		21%		19%	19%	21%	20%	21%	18%	18%	14%
Number reporting direct sharing	45	46		51		26	46	39	29	27	21	20	19
Total number answering question	258	263		240		139	243	184	145	127	114	111	134
Level of sharing (direct & indirect) ^{††}	41%	34%		39%		38%	43%	46%	49%	45%	42%	34%	32%
Number reporting sharing	103	90		93		53	104	85	72	57	50	38	43
Total number answering question	249	265		241		139	240	185	147	128	118	111	134
Proportion injecting crack	26%	23%		22%		29%	30%	31%	28%	40%	50%	45%	61%
Number reporting crack injection	68	60		52		40	73	56	43	53	57	49	82
Total number answering question	259	261		241		139	241	183	152	131	115	110	135
Proportion injecting into their groin	13%	19%		12%		14%	13%	17%	13%	15%	17%	14%	16%
Number reporting groin injection	33	50		30		19	31	33	20	20	20	16	22
Total number answering question	249	259		248		140	244	190	151	132	118	112	136
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	21%	17%		23%		21%	15%	18%	24%	15%	16%	25%	17%
Number always using a condom	24	23		34		19	17	15	15	9	8	13	8
Total number answering question	116	135		146		91	116	84	63	59	51	53	46

^{*} Due to changes in survey questions regarding awareness of HCV infection status, data from 2017 are not directly comparable to data from previous years. Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data

Table 25: Self-reported overdosing in the last year among current injectors by gender, age, time since first injected and treatment status; naloxone use and carriage; England, Wales and Northern Ireland: 2013-2018

			Year					
			2013	2014	2015	2016	2017	2018
All		Proportion overdosing in preceding year	16%	17%	20%	19%	18%	21%
		Number overdosing in preceding year	326	348	361	369	308	383
		Total number answering question	2,077	2,034	1,851	1,901	1,703	1,786
Gender ~	Male	Proportion overdosing in preceding year	16%	17%	20%	20%	18%	21%
		Number overdosing in preceding year	251	259	278	274	217	269
		Total number answering question	1,553	1,514	1,371	1,400	1,225	1,303
	Female	Proportion overdosing in preceding year	14%	17%	17%	19%	19%	23%
		Number overdosing in preceding year	74	88	83	93	90	111
		Total number answering question	512	515	477	497	470	477
Age ~	Under 25	Proportion overdosing in preceding year	23%	27%	33%	25%	16%	42%
		Number overdosing in preceding year	33	38	32	14	9	22
		Total number answering question	146	143	96	57	56	53
	25 to 34	Proportion overdosing in preceding year	15%	18%	22%	24%	22%	26%
		Number overdosing in preceding year	120	128	135	140	106	117
		Total number answering question	809	710	609	588	487	456
	35 and over	Proportion overdosing in preceding year	15%	15%	17%	17%	17%	19%
		Number overdosing in preceding year	165	174	193	211	188	237
		Total number answering question	1,098	1,158	1,137	1,237	1,134	1,259
Time since first injected	≤3 years (recent initiates)	Proportion overdosing in preceding year	22%	21%	24%	19%	21%	20%
		Number overdosing in preceding year	52	44	48	30	32	35
		Total number answering question	237	205	198	161	154	176
	>3 years	Proportion overdosing in preceding year	14%	16%	19%	19%	18%	21%
Number overdosing in preceding year		254	289	308	329	263	331	
Total number answering question		1,773	1,779	1,610	1,694	1,494	1,564	
Treatment status	Never in treatment/ not known	Proportion overdosing in preceding year	17%	15%	21%	19%	23%	31%
		Number overdosing in preceding year	52	51	61	54	30	35
		Total number answering question	305	342	285	288	132	113
	Previously in treatment	Proportion overdosing in preceding year	21%	26%	26%	31%	21%	27%
		Number overdosing in preceding year	70	73	74	95	52	86
		Total number answering question	330	277	285	307	247	316
Currently in treatment	Proportion overdosing in preceding year	14%	16%	18%	17%	17%	19%	
	Number overdosing in preceding year	202	223	226	215	224	261	
	Total number answering question	1,436	1,406	1,275	1,300	1,313	1,344	
Naloxone use								
Among those who report an overdose in the last year		Proportion who had naloxone administered	44%	44%	54%	48%	50%	55%
		Number who had naloxone administered	111	129	161	148	128	164
		Total number answering question	254	292	300	309	258	298
Among those who report an overdose in the last year who are currently or previously in treatment		Proportion who had naloxone administered	45%	44%	55%	48%	50%	56%
		Number who had naloxone administered	94	109	138	127	117	153
		Total number answering question	210	249	250	265	234	271
Naloxone availability								
All		Proportion who carry naloxone					54%	65%
		Number who carry naloxone					879	1,156
		Total number answering question					1,617	1,789

Please refer to page 4 for additional abbreviations and footnotes to assist in interpreting this data